ChemoCentryx Stock Forecast, Price & News

-0.09 (-0.54 %)
(As of 09/20/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume1.76 million shs
Average Volume2.07 million shs
Market Capitalization$1.15 billion
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive CCXI News and Ratings via Email

Sign-up to receive the latest news and ratings for ChemoCentryx and its competitors with MarketBeat's FREE daily newsletter.

ChemoCentryx logo

About ChemoCentryx

ChemoCentryx, Inc. is a biopharmaceutical company engages in the development and commercialization of medicines. It focuses on inflammatory disorders, autoimmune diseases, and cancer. Its drug candidates such as Avacopan and CCX140, selectively blocks a specific chemoattractant receptor, leaving the rest of the immune system intact. The company was founded by Thomas J. Schall in 1997 and is headquartered in San Carlos, CA.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.92 out of 5 stars

Medical Sector

656th out of 1,352 stocks

Pharmaceutical Preparations Industry

317th out of 665 stocks

Analyst Opinion: 3.3Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

ChemoCentryx (NASDAQ:CCXI) Frequently Asked Questions

Is ChemoCentryx a buy right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ChemoCentryx in the last year. There are currently 1 sell rating, 2 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ChemoCentryx stock.
View analyst ratings for ChemoCentryx
or view top-rated stocks.

What stocks does MarketBeat like better than ChemoCentryx?

Wall Street analysts have given ChemoCentryx a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but ChemoCentryx wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is ChemoCentryx's next earnings date?

ChemoCentryx is scheduled to release its next quarterly earnings announcement on Monday, November 8th 2021.
View our earnings forecast for ChemoCentryx

How were ChemoCentryx's earnings last quarter?

ChemoCentryx, Inc. (NASDAQ:CCXI) issued its quarterly earnings results on Sunday, August, 8th. The biopharmaceutical company reported ($0.56) EPS for the quarter, missing the Zacks' consensus estimate of ($0.55) by $0.01. The biopharmaceutical company earned $1.81 million during the quarter, compared to analyst estimates of $4.85 million. ChemoCentryx had a negative trailing twelve-month return on equity of 33.17% and a negative net margin of 568.54%. The business's revenue was down 96.3% compared to the same quarter last year. During the same quarter last year, the firm posted $0.29 EPS.
View ChemoCentryx's earnings history

How has ChemoCentryx's stock been impacted by Coronavirus (COVID-19)?

ChemoCentryx's stock was trading at $41.54 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, CCXI stock has decreased by 60.3% and is now trading at $16.48.
View which stocks have been most impacted by COVID-19

What price target have analysts set for CCXI?

8 brokers have issued twelve-month target prices for ChemoCentryx's shares. Their forecasts range from $17.00 to $70.00. On average, they expect ChemoCentryx's stock price to reach $37.88 in the next twelve months. This suggests a possible upside of 129.8% from the stock's current price.
View analysts' price targets for ChemoCentryx
or view top-rated stocks among Wall Street analysts.

Who are ChemoCentryx's key executives?

ChemoCentryx's management team includes the following people:
  • Thomas J. Schall, Chairman, President & Chief Executive Officer
  • Tausif Butt, Chief Operating Officer & Executive Vice President (LinkedIn Profile)
  • Susan M. Kanaya, Chief Financial Officer, Secretary & Director
  • Sangita Ghosh, Senior Vice President-Technical Operations
  • Markus J. Cappel, Treasurer & Chief Business Officer

What is Thomas J. Schall's approval rating as ChemoCentryx's CEO?

10 employees have rated ChemoCentryx CEO Thomas J. Schall on Thomas J. Schall has an approval rating of 58% among ChemoCentryx's employees. This puts Thomas J. Schall in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of ChemoCentryx's key competitors?

What other stocks do shareholders of ChemoCentryx own?

What is ChemoCentryx's stock symbol?

ChemoCentryx trades on the NASDAQ under the ticker symbol "CCXI."

Who are ChemoCentryx's major shareholders?

ChemoCentryx's stock is owned by many different retail and institutional investors. Top institutional investors include Jefferies Group LLC (0.00%), FMR LLC (14.97%), Vanguard Group Inc. (6.95%), State Street Corp (6.76%), BlackRock Inc. (6.68%) and RA Capital Management L.P. (5.00%). Company insiders that own ChemoCentryx stock include (International) Ltd Vifor, Geoffrey M Parker, James L Tyree, Markus J Cappel, Pui San Kwan, Susan M Kanaya, Tausif Butt, Thomas A Edwards and Thomas J Schall.
View institutional ownership trends for ChemoCentryx

Which institutional investors are selling ChemoCentryx stock?

CCXI stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Nuveen Asset Management LLC, International Biotechnology Trust PLC, Bank of America Corp DE, California Public Employees Retirement System, Tekla Capital Management LLC, RA Capital Management L.P., and Alliancebernstein L.P.. Company insiders that have sold ChemoCentryx company stock in the last year include Geoffrey M Parker, James L Tyree, Markus J Cappel, Pui San Kwan, Thomas A Edwards, and Thomas J Schall.
View insider buying and selling activity for ChemoCentryx
or view top insider-selling stocks.

Which institutional investors are buying ChemoCentryx stock?

CCXI stock was purchased by a variety of institutional investors in the last quarter, including Jefferies Group LLC, State Street Corp, Susquehanna International Group LLP, Ikarian Capital LLC, Parallax Volatility Advisers L.P., Simplex Trading LLC, Squarepoint Ops LLC, and Citigroup Inc..
View insider buying and selling activity for ChemoCentryx
or or view top insider-buying stocks.

How do I buy shares of ChemoCentryx?

Shares of CCXI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ChemoCentryx's stock price today?

One share of CCXI stock can currently be purchased for approximately $16.48.

How much money does ChemoCentryx make?

ChemoCentryx has a market capitalization of $1.15 billion and generates $64.89 million in revenue each year. The biopharmaceutical company earns $-55,360,000.00 in net income (profit) each year or ($0.84) on an earnings per share basis.

How many employees does ChemoCentryx have?

ChemoCentryx employs 133 workers across the globe.

What is ChemoCentryx's official website?

The official website for ChemoCentryx is

Where are ChemoCentryx's headquarters?

ChemoCentryx is headquartered at 850 MAUDE AVENUE, MOUNTAIN VIEW CA, 94043.

How can I contact ChemoCentryx?

ChemoCentryx's mailing address is 850 MAUDE AVENUE, MOUNTAIN VIEW CA, 94043. The biopharmaceutical company can be reached via phone at (650) 210-2900 or via email at [email protected].

This page was last updated on 9/20/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.